Are Medical Stocks Lagging Annexon (ANNX) This Year?

Group 1 - Annexon, Inc. (ANNX) is currently outperforming the Medical sector, gaining approximately 12.7% year-to-date, while the sector has lost about 0.1% on average [2] - The Zacks Consensus Estimate for ANNX's full-year earnings has increased by 21.1% over the past three months, indicating stronger analyst sentiment and an improving earnings outlook [2] - Annexon, Inc. holds a Zacks Rank of 2 (Buy), reflecting its potential to outperform the market in the near term [1] Group 2 - Annexon, Inc. is part of the Medical - Biomedical and Genetics industry, which consists of 506 individual stocks and currently ranks 82 in the Zacks Industry Rank [3] - The Medical - Biomedical and Genetics industry has experienced an average loss of 8.2% so far this year, highlighting Annexon's better performance within this group [3] - Another stock in the same industry, Adma Biologics (ADMA), has also outperformed the sector with a year-to-date return of 36.3% and a Zacks Rank of 1 (Strong Buy) [2][3]